• Accumulated registered mums on the HeraMED platform at 4,367 as at 30 June 2025
• Partnership with RMIT and Digital Health CRC to advance AI driven maternity care
• Appointment of Aspire Health Innovations and Jeff Garibaldi to accelerate US growth

HeraMED Limited (ASX:HMD) has provided its Appendix 4C cashflow statement for the June 2025 quarter (Q2 FY25) along with a review of operations. The company reported that the number of accumulated registered mums on the HeraCARE platform reached 4,367 as at 30 June 2025, including 181 active users. HeraMED also entered into a research and development partnership with RMIT and the Digital Health Cooperative Research Centre to focus on improving maternal health outcomes through the collection and use of data sets including culturally and linguistically diverse (CALD) women using AI-enabled predictive care. The company appointed Aspire Health Innovation, a leading US healthcare commercialization firm, to accelerate its US go-to-market strategy and commercial growth. HeraMED also welcomed Jeff Garibaldi as Chief Growth Officer US, bringing extensive US healthcare leadership and commercialization experience. The company faced some challenges in the US market, with Broward Health discontinuing its use of HeraCARE despite positive maternal-fetal outcomes. However, HeraMED remains focused on progressing its four-point strategy and is optimistic about its future outlook, with progress in several ongoing discussions with potential customers and new conversations in its commercial pipeline.

The company expects further optimization in research & development functions for the HeraCARE platform with a restructure and transition plan for the technical team about to be finalized and implementation to happen over 2025. This move is part of the company's ongoing commitment to operational efficiency and cost management.

HeraMED remains focused on progressing the key pillars of its four-point strategy, with commercial agreements being a core strategic priority. The company has used the June 2025 quarter to review and adapt to the changing landscape to further align its operational, functional, regulatory, and sales efforts, and diversify market opportunities to support the execution of its plan.